Capital International Investors Makes New Investment in Cellebrite DI Ltd. $CLBT

Capital International Investors bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,278,040 shares of the company’s stock, valued at approximately $41,073,000.

Other large investors have also bought and sold shares of the company. Goldman Sachs Group Inc. raised its holdings in shares of Cellebrite DI by 34.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 264,918 shares of the company’s stock valued at $4,776,000 after purchasing an additional 67,280 shares during the last quarter. Walter Public Investments Inc. purchased a new position in shares of Cellebrite DI during the fourth quarter valued at approximately $9,242,000. Rock Creek Group LP purchased a new position in shares of Cellebrite DI during the fourth quarter valued at approximately $2,704,000. Geode Capital Management LLC raised its holdings in shares of Cellebrite DI by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 371,739 shares of the company’s stock valued at $6,700,000 after purchasing an additional 31,855 shares during the last quarter. Finally, King Luther Capital Management Corp raised its holdings in shares of Cellebrite DI by 17.6% during the fourth quarter. King Luther Capital Management Corp now owns 354,184 shares of the company’s stock valued at $6,386,000 after purchasing an additional 52,945 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Trading Down 3.4%

Shares of NASDAQ CLBT opened at $12.98 on Wednesday. The firm has a 50 day moving average of $13.27 and a 200 day moving average of $15.12. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of 46.36, a price-to-earnings-growth ratio of 1.66 and a beta of 1.17. Cellebrite DI Ltd. has a 12-month low of $11.02 and a 12-month high of $19.98.

Analyst Ratings Changes

Several research firms have recently weighed in on CLBT. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, DA Davidson began coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Insider Transactions at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 13,269 shares of company stock worth $169,592 in the last three months. Insiders own 5.70% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.